Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the ...

CVS Caremark must now shoulder nearly $290 million in damages and penalties after being found complicit in a Medicare Part D ...

Notably, the case came from a whistleblower lawsuit filed by Sarah Behnke, a former Medicare Part D actuary at Aetna, who ...

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

A federal judge has ordered CVS Caremark to pay almost $290 million in damages and penalties after a whistleblower proved the ...

A federal judge has ordered CVS Caremark to pay nearly $290 million in damages after determining the pharmacy benefit manager overbilled Medicare for prescription drugs, according to court documents ...

CVS has emerged as an outlier during the ongoing implosion observed in the healthcare insurance sector, as they drive ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Through the power of strategic, well-built partnerships, CVS Health helps employees earn degrees — and at no cost to them.

CVS Health hiked its 2025 forecast above Wall Street’s expectations after improving Medicare benefits contributed to a better-than-expected first quarter.

Overall, CVS Health booked adjusted earnings of $2.25 per share as the company’s profit soared 60% to $1.78 billion in the year’s first quarter. Total revenue climbed 7% to $94.59 billion.